title: [Effect of probiotics on proinflammatory cytokines level in patients with type 2 diabetes and nonalcoholic fatty liver disease].
abstract: We examined 72 patients with T2D and NAFLD. All patients divided by us on the way of therapy into 2 groups. The main group (n = 45) received oral antidiabetic therapy and multiprobiotic "Symbiter" within 30 days. Patients of comparison group (n = 27) received only hypoglycemic drugs. Also in each group we identified patients with normal and elevated level of transaminases. We observed 1.5-2 times increasing of cytokines in patients with NAFLD and elevated transaminase levels compared to patients with normal transaminase levels. We noted statistically significant reduction of proinflammatory cytokines in plasma, after 30 days of therapy, in patients with elevated levels of transaminases. In particular, the level of IL-6 decreased on 30.9% (P < 0.001), IL-8 - 19.9% (P = 0.001), TNF-alpha - 13.4% (P < 0.001), IL-1beta - 17.9% (P < 0.001) and IFN-gamma on 18.7% (P < 0.001) respectively. In patients with normal levels transaminases and NAFLD were significantly decreased only TNF-alpha on 15.1% (P = 0.003) and IL-8 on 15.2% (P = 0.017). Significant changes in cytokines levels in patients of comparative group we don't observed. Probiotics can be recommended for use in patients with different stages of NAFLD and T2D as an adjunct to standard treatment regimens because it decreases manifestations of low-grade systemic inflammatory response.
authors.forename: H P
authors.initials: HP
authors.lastname: Mykhal'chyshyn
authors.forename: P M
authors.initials: PM
authors.lastname: Bodnar
authors.forename: N M
authors.initials: NM
authors.lastname: Kobyliak
mesh_terms: D003131:Combined Modality Therapy; D016207:Cytokines / Q000097:blood / Q000276:immunology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D005234:Fatty Liver / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use*; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome
chemical_list: D016207:Cytokines; D007004:Hypoglycemic Agents; D000637:Transaminases